Big pharmaceutical companies, seeking new pathways in cancer treatment, are increasing investments in antibody drug conjugates (ADCs) developed by biotech firms. BMS recently purchased of an ADC from South Korean biotech Orum Therapeutics for $100m. The development of ADCs involves combining chemotherapies with monoclonal antibodies to specifically target cancer cells, reducing side-effects. ADCs are valued at $9.7bn in 2023 and are expected to double to $19.8bn in five years.
Critical Claude Code Flaw Silently Bypasses User-Configured Security Rules
Anthropic’s flagship AI coding agent, Claude Code, was recently discovered to contain a critical security flaw that silently bypasses developer-configured safety rules. The vulnerability allows
